drugset / Trial / NCT00690911

Study to Determine the Efficacy of Adalimumab in the Treatment of Cutaneous Sarcoidosis

NCT00690911 ↗

Phase 2 Withdrawn Wake Forest University
NaSingle-groupOpen-labelTreatment

Summary

The purpose of the study is to see if Humira is effective and safe in the treatment of sarcoidosis.

Timeline

Start
—
Primary completion
—
Completion
—

Outcome

Outcome not reported

Stopped: “Dr. Jorizzo has decided to withdraw from this study due to the time it is taking to get the study started.”

Drugs

EvaluationDrugModalityDoseRoute
Subject Adalimumab Monoclonal antibody 40 mg Subcutaneous

Indications